Clinical Trial Update: Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology

View source ↗

Summary

The trial evaluating Retacrit (epoetin zeta), a biosimilar, for chemotherapy-induced symptomatic anemia in hematology and oncology has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Anemia
• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• RETACRIT (EPOETIN ALFA-EPBX)

Snippet

Sponsor: Hospira, now a wholly owned subsidiary of Pfizer | Conditions: Chemotherapy-induced Symptomatic Anaemia, Solid Tumours | Status: COMPLETED